European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma Oct 28, 2019 02:00PM
Merck KGaA, Pfizer (PFE) Announce CHMP Adopts Positive Opinion for BAVENCIO Plus Axitinib for First-Line Treatment of Patients with Advanced RCC Sep 20, 2019 08:11AM
CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma Sep 20, 2019 08:10AM